ArticleCurrent medical science2026
Huaiqihuang Alleviates Imiquimod-Induced Psoriasis-Like Skin Lesions and Depressive-Like Behaviors in Mice.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveDepression is a significant comorbidity of psoriasis, prompting an exploration of the potential use of traditional Chinese medicine for the concurrent treatment of both conditions. This study aimed to investigate the effects of Huaiqihuang (HQH) on psoriasis and its comorbid depressive-like behavior in a murine model.
methodsWe utilized an imiquimod (IMQ)-induced psoriasis-like model to mimic psoriasis and concurrent depression. The mice received oral HQH extract, and subsequent assessments were performed to monitor changes in skin lesions, inflammatory cells, and depressive behaviors. A network pharmacology approach was used to identify target genes for protein‒protein interaction analysis, and potential signaling pathways were suggested. Based on the above prediction results, we investigated the effects of HQH on Th17 cell levels in the brains, skin-draining lymph nodes, and spleens of model mice to elucidate the underlying mechanisms.
resultsOur results revealed a significant reduction in the mouse skin PASI score and pathological score following HQH treatment. Furthermore, HQH had inhibitory effects on CD3
conclusionsHQH reduced psoriasis skin lesions, relieved depressive-like behaviors and decreased the abundance of Th17 cells in the spleen, lymph nodes, and brain, suggesting the promise of traditional Chinese medicine for managing psoriasis and its comorbidities by targeting Th17 cells.
Indexed as
Identifiers
42753093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.